This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities
by
Eugenia Veronica Di Brizzi
Eugenia Veronica Di Brizzi
,
Stefano Caccavale
Stefano Caccavale
Caterina Mariarosaria Giorgio
Caterina Mariarosaria Giorgio
Giuseppe Argenziano
Giuseppe Argenziano
Giuseppe Argenziano is a full professor and head of the Dermatology Unit at the University of Italy, [...]
Giuseppe Argenziano is a full professor and head of the Dermatology Unit at the University of Campania, Naples, Italy, co-founder and past president of the International Dermoscopy Society, and president of the Italian Society of Dermatology. His main research field is dermato-oncology, and he is the author of numerous scientific articles and books concerning dermoscopy, melanoma, and non-melanoma skin cancer. As coordinator of the Melanoma Unit at Campania University, he has established a successful tertiary, multidisciplinary referral center particularly devoted to the diagnosis and management of patients with skin cancer.
Anna Balato
Anna Balato
Dermatology Unit, University of Campania “L. Vanvitelli”, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
Life 2025, 15(7), 1026; https://doi.org/10.3390/life15071026 (registering DOI)
Submission received: 28 May 2025
/
Revised: 16 June 2025
/
Accepted: 25 June 2025
/
Published: 27 June 2025
Abstract
Psoriasiform dermatitis refers to a spectrum of inflammatory skin disorders that resemble psoriasis both clinically and histologically. These conditions can occur idiopathically or as paradoxical reactions to biologic or targeted therapies, particularly in patients with atopic or autoimmune backgrounds. Histologic features often include acanthosis, parakeratosis, and lymphocytic infiltrates, but without the full molecular signature of classical psoriasis. This review provides an overview of psoriasiform dermatitis with a focus on its clinical presentation, differential diagnosis, and the immune pathways involved. Drug-induced forms, especially those triggered by anti-TNF agents, IL-4/IL-13 blockers, and JAK inhibitors, are highlighted due to their growing clinical relevance. We also summarize the main topical and systemic treatments, including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and JAK-STAT- or IL-23-targeted therapies. A better understanding of psoriasiform dermatitis is crucial to improve diagnosis and to guide treatment, especially in complex or refractory cases.
Share and Cite
MDPI and ACS Style
Di Brizzi, E.V.; Caccavale, S.; Giorgio, C.M.; Argenziano, G.; Balato, A.
Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life 2025, 15, 1026.
https://doi.org/10.3390/life15071026
AMA Style
Di Brizzi EV, Caccavale S, Giorgio CM, Argenziano G, Balato A.
Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life. 2025; 15(7):1026.
https://doi.org/10.3390/life15071026
Chicago/Turabian Style
Di Brizzi, Eugenia Veronica, Stefano Caccavale, Caterina Mariarosaria Giorgio, Giuseppe Argenziano, and Anna Balato.
2025. "Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities" Life 15, no. 7: 1026.
https://doi.org/10.3390/life15071026
APA Style
Di Brizzi, E. V., Caccavale, S., Giorgio, C. M., Argenziano, G., & Balato, A.
(2025). Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life, 15(7), 1026.
https://doi.org/10.3390/life15071026
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.
